Your search history is turned on.
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia
Ceapro Inc. Reports 2023 Financial Results and Operational Highlights 2023 marked by Ceapros achievement of key milestones and progress toward its next phase of growth R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the building of pilot scale units for PGX Technology Sales impacted (decreased by 49% from $18.8...
Annual Form 52-109FV1-Annual-CFO-Ceapro-conformed signature (E4314201).DOCX FORM 52-109F2 -- FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Stacy Prefontaine, Chief Financial Officer of Ceapro Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for g...
Annual Form 52-109FV1-Annual-CEO-Ceapro-conformed signature (E4314197).DOCX FORM 52-109F2 -- FV1 CERTIFICATION OF ANNUAL FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Gilles Gagnon, Chief Executive Officer of Ceapro Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for great...
Microsoft Word - MD&A 2023_Q4 V9 Clean.docx 1 The MD&A provides commentary on the results of operations for the year ended December 31, 2023, and 2022, the financial position as at December 31, 2023 and 2022, and the outlook of Ceapro Inc. (Ceapro and the Company) based on information available as at April 24, 2024. The following information should be read ...
Date: April 29, 2024 Jurisdictions: Alberta
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Consolidated Financial Statements for the Years Ended December 31, 2023 and 2022 Ceapro Inc. Managements Report To the Shareholders of Ceapro Inc., The accompanying consolidated financial statements of Ceapro Inc. (the "Company"), and all information presented in this report, are the responsibility of Management and have been approved by the Board of ...
Date: March 28, 2024 Jurisdictions: Alberta, British Columbia
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, March 28, 2024 Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (Ceapro) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described...
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, Alberta, March 28, 2024 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (Ceapro) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement...
Date: March 12, 2024 Jurisdictions: Alberta, British Columbia
Microsoft Word - CALGARY-#31432323-v5-WestJet_2019_Special_Meeting_Report_on_Voting_SEDAR_(Blakes_draft).DOCX Report on Voting Results Pursuant to Section 11.3 of National Instrument 51-102 Continuous Disclosure Obligations At the special meeting of shareholders and optionholders (collectively, the Securityholders) of Ceapro Inc. (Ceapro or the Company...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings TORONTO and EDMONTON, Alberta, March 12, 2024 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (Ceapro) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of equals transaction (the Transac...